4-methoxyhonokiol has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, L; Cai, L; Guo, H; Kim, KS; Kim, KT; Lian, X; Ma, T; Rane, MJ; Zhang, Z; Zheng, Z | 1 |
| Bi, L; Cai, L; Guo, H; Kim, KS; Kim, KT; Ma, T; Zhang, Z; Zheng, Z | 1 |
2 other study(ies) available for 4-methoxyhonokiol and Alloxan Diabetes
| Article | Year |
|---|---|
4-O-methylhonokiol ameliorates type 2 diabetes-induced nephropathy in mice likely by activation of AMPK-mediated fatty acid oxidation and Nrf2-mediated anti-oxidative stress.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Antioxidants; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, High-Fat; Enzyme Activation; Fatty Acids; Insulin Resistance; Kidney; Lignans; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Oxidation-Reduction; Oxidative Stress; Phytotherapy | 2019 |
4-O-methylhonokiol protects against diabetic cardiomyopathy in type 2 diabetic mice by activation of AMPK-mediated cardiac lipid metabolism improvement.
Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fibrosis; Inflammation; Lignans; Lipid Metabolism; Male; Mice, Inbred C57BL; Models, Biological; Oxidative Stress | 2019 |